

Exhibit 79

Board of Directors: Ethics & Compliance Update

June 2017

Maggie Feltz



PROPRIETARY AND CONFIDENTIAL

U.S. - 36

Executive Summary

- There are no significant compliance issues to report
- We met all “business as usual” requirements and are continuously improving
- We have continued our focus on enhancing commercial controls in response to the external environment
- The Ethics & Compliance team has made progress toward several important objectives and collaborated with the business to support risk mitigation
 - Through Enterprise Risk Assessment (ERA) we have engaged with the business to support risk mitigation
 - Cross functional teams collaborated to mitigate risks and ensure fidelity to the Setting the New Standard (STNS) corporate objective
 - We are transforming our Code of Business Ethics to support principles-based decision-making and are engaged in overall policy improvements
 - We are collaborating to improve confidential reporting, investigation and non-retaliation practices
 - We are timely meeting our regulatory reporting requirements – most notably Sunshine Act Reporting




PROPRIETARY AND CONFIDENTIAL

1

U.S. - 37

We are meeting all “business as usual” requirements and are continuously improving



Element	Our Program Highlights
Compliance Officer & Committees	<ul style="list-style-type: none">• Suspicious Order Monitoring Committee routinely meeting and functioning well• Corporate Compliance Council resumed; scheduled for remainder of 2017• Corporate Risk Council being formed to identify and mitigate significant risks
Standards & Procedures	<ul style="list-style-type: none">• Code of Business Ethics update reflecting shift toward principles-based decision making• Creation/Update of SOPs for Sales Ops, OTC franchise, Public Affairs, Medical Affairs
Lines of Communication	<ul style="list-style-type: none">• Hotline volume - predominantly external inquiries related to medical questions• Lower than benchmark percentage anonymous calls
Training & Education	<ul style="list-style-type: none">• Deployment of updated <i>Healthcare Law Compliance Policies</i> module• Hotline and other reminders emphasizing non-retaliation practices
Auditing & Monitoring	<ul style="list-style-type: none">• Completed audit of field coaching reports (FCRs)• E&C Ride alongs continuing but will increase post Symproic® launch• Call notes to focus on new hires, new product launches• Speaker program monitoring continues; increase anticipated as Hysingla programs resume and Symproic programs begin
Investigations & Disclosures	<ul style="list-style-type: none">• Collaboration with HR, Law, Security to enhance quality of investigations processes
Enforcement & Discipline	<ul style="list-style-type: none">• Primary Action Taken for investigations continues to be predominantly coaching (8%) and advising (12%) but terminations (7%) and warning letters (7%) have both occurred in 2017, when warranted.



PROPRIETARY AND CONFIDENTIAL

2

U.S. - 38

We have continued our focus on enhancing commercial controls in response to the external environment

Issue	Monitoring and Enhancements
Management Oversight	<ul style="list-style-type: none">Improved field management oversight through increased field ride alongsEnhanced Field Coaching Report formatDecreased span of control for DBMs – previously 1:11, now capped at 1:9Inclusion of KPIs in manager incentive compensation (IC)
Appropriate Messaging	<ul style="list-style-type: none">Prescriptive support around opioidsCore Visual Aids revised to ensure fidelity to approved messagingOptimized the IC plan to support Setting the New Standard (STNS) for Responsible Opioid Prescribing & Education
Marketing	<ul style="list-style-type: none">Limited number of Purdue personnel calling on customersEnhanced prescriptive call plans – defined reach and frequencyAssessing and optimizing frequency of non-personal promotion (eDetail)
Sales	<ul style="list-style-type: none">Reiterating messaging to the field regarding IC focus on market share/market share change rather than volumeEmphasize strong commitment to non-retaliation policyEncourage reporting of all known or suspected concerns



PROPRIETARY AND CONFIDENTIAL

3

U.S. - 39

Through Enterprise Risk Assessment (ERA) we have engaged with the business to support risk mitigation

	Element	Status		Element	Status
Commercial	Review HCP Tools & Develop Website Access	<div></div>	Medical	Update Med Info Requests; Ensure After-Hours Support	<div></div>
	Review Forecasting & Analytics	<div></div>		Review Grants and Funding for Third Party Orgs.	<div></div>
	Reduce Speaker Programs	<div></div>		Evaluate Patient Assistance Programs	<div></div>
	Reduce Co-Pay Card Programs	<div></div>		Review Status of IR/ER Study	
	Reduce Unbranded Corporate Websites	<div></div>		Assess Medical Science Committee Composition	<div></div>
	Reduce Unbranded Marketing Websites	<div></div>		Data Review and Disclosure Policy	<div></div>
	Eliminate RxHub Program	<div></div>		Evaluate Sales Rep/MSL Model	<div></div>
	Update Branded Website & Materials	<div></div>		Rename Strategic External Experts Database	<div></div>
	Reduce Volume of Branded Materials	<div></div>			
	Enhance Sales Training	<div></div>			
	Verify Viability of Med Therapy Management				
	Review Compensation Plans	<div></div>			
	Element	Status		Element	Status
Public Affairs	Replace Moderator of Pain Care Forum	<div></div>	Law and Compliance	Enhance Vendor Adverse Event Reporting	<div></div>
	Develop Company Policy Positions	<div></div>		Increase Vendor Onboarding Training	<div></div>
	Review Company Role in Pain Therapeutics	<div></div>		Enhance Abuse & Diversion Detection Program	<div></div>
				Enhance Suspicious Order Monitoring Program	<div></div>
		Train on IP/Digital Resource Center		<div></div>	
			Grow Purdue IQ – Employee Training & Awareness	<div></div>	
			Ensure Documentation Controls	<div></div>	
	Inactive	<div></div>		In Progress	<div></div>
		<div></div>		Completed	<div></div>

Cross functional teams collaborated to mitigate risks and ensure fidelity to STNS corporate objective

Review Grants & Funding to 3rd Parties



Evaluate Patient Assistance Programs



Enhance Suspicious Order Monitoring




PROPRIETARY AND CONFIDENTIAL

5

U.S. - 41

We are transforming our Code of Business Ethics and updating policies to improve decision making



PROPRIETARY AND CONFIDENTIAL

6

U.S. - 42

We are collaborating to improve confidential reporting, investigation and non-retaliation practices




PROPRIETARY AND CONFIDENTIAL

7

U.S. - 43

We are meeting our regulatory reporting requirements and timing, particularly Sunshine Act Reporting

Spend (\$M) / Number of records and disputes



Note: General Spend includes items such as speaker programs, HCP in-office meals, and HCP fee-for-service contracts. These items will be made public by CMS on June 30, 2017; research Spend is subject to a delay of up to 4 years to preserve confidential research activities

¹ Only includes August - December



PROPRIETARY AND CONFIDENTIAL

8

U.S. - 44

Appendix




PROPRIETARY AND CONFIDENTIAL


U.S. - 45

Investigations and Inquiries: Q12017

Incident Category (Total PRs)



Incidents – Days to Close



INCIDENT REPORT ACTIVITY SUMMARY

	PTD		YTD		YTD Market Comparison
	5	%	34	%	
Original Incident Reports					
Anonymous Reports	0	0.0%	4	11.8%	42.3%
Non-Anonymous Reports	5	100.0%	30	88.2%	57.7%

- Our year-to-date anonymous report percentage is 11.8% as compared to 42.3% for the market comparison from our hotline vendor.
 - For comparison, in 2016, 27% of calls to our hotline were made anonymously vs. market comparison of 40.7%
- Anonymous calls are harder to properly and completely investigate. Employing more awareness and anti-retaliation training may empower more employees to identify themselves when the contact the Hotline.




PROPRIETARY AND CONFIDENTIAL

10


U.S. - 46

Types of Incidents and Actions Taken: Q12017

We are running at approximately the same rate for each category as previous years, other than HR matters, where we are slightly higher at this point in the year than in previous years



Primary action taken is consistent with previous periods



Note: Graphs represent closed matters only



PROPRIETARY AND CONFIDENTIAL

11

U.S. - 47